Instructions for Relugolix

1. Common name: Regrek

Product name:Orgovyx

All names: relugolix, relugolix,relugolix tablets

2. Indications:

Relugolix (Relugolix) is suitable for the treatment of adult patients with advanced prostate cancer.

3. Usage and dosage:

1. Recommended dose: The patient starts treatment with Repagliflozin at a loading dose of 360 mg on the first day, and continues oral treatment at a dose of 120 mg, once a day. Regaglic can be taken with or without food. If treatment with regaglic is interrupted for more than 7 days, restart regaglic at a loading dose of 360 mg on the first day and continue at a dose of 120 mg once daily.

2. Dose adjustment: For prostate cancer patients who receiveGnRH receptor agonists and antagonists, treatment is usually continued when non-metastatic or metastatic castration-resistant prostate cancer develops.

(1) ForP-gp inhibitors: Avoid coadministration of repagliflozin with oral P-gp inhibitors. If coadministration cannot be avoided, repagliflozin should be taken first and separated by at least 6 hours between doses. If short-term treatment with a P-gp inhibitor is necessary, treatment with Repaglica may be interrupted for up to two weeks.

(2) For use in combination with P-gp and strong CYP3A inducers: Avoid coadministration of repagliflozin with combinations of P-gp and strong CYP3A inducers. If unavoidable, increase the repaglic dose to 240 mg once daily; after discontinuation of combined P-gp and strong CYP3A inducers, resume the recommended dose of repaglic at 120 mg once daily.

4. Adverse reactions:

In clinical studies of Repagliflox, the most common adverse reactions (≥10%) and laboratory abnormalities (≥15%) were hot flashes, increased glucose, increased triglycerides, musculoskeletal pain, decreased hemoglobin, increased alanine aminotransferase (ALT), fatigue, increased aspartate aminotransferase (AST), constipation and diarrhea; serious adverse reactions included myocardial infarction, acute kidney injury, cardiac arrhythmia, bleeding and urinary tract infection. Adverse events such as allergies, including angioedema and urticaria, have occurred after regoglik was launched on the market.

5. Storage:

Store Repagliflozin at room temperature, not above30°C (86°F). Distribute to patients only in original containers. For bottles, keep the container tightly closed after first opening. Keep out of reach of children.

6. Taboo:

Relugolix is contraindicated in patients with severe allergyto relugolix or any product ingredient.

7. Mechanism of action:

Regolic is a non-peptideGnRH receptor antagonist that competitively binds to the pituitary GnRH receptor, thereby reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby reducing the release of testosterone.